Photo of Chin Hur,  MD, MPH

Chin Hur, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital

Chin Hur, MD, MPH

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Director, GI Health Outcomes Research, Gastrointestinal Unit, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Hur's areas of clinical areas of interests include: gastroesophageal reflux disease (GERD), Barrett's esophagus, esophageal adenocarcinoma as well as gastrointestinal cancer screening. His research interest lies in outcomes research, specifically technology assessment with a focus on decision analysis and disease modeling, and the application of these methodologies to the management of cancers and pre-malignant states (e.g. dysplasia) in the gastrointestinal tract. This management includes the identification of clinical predictors, diagnostic algorithms, and the optimization of treatment.

Some of the representative projects that he has worked on include a Simulation Model of Esophageal Adenocarcinoma, a Markov Model of Duodenal Polyposis in Familial Adenomatous Polyposis (FAP), an analysis of the impact of the implementation of Virtual Colonoscopies for colorectal cancer (CRC) screening and the possible role for chemoprevention in cancer care.

Current Projects:

- Disease model (Markov Monte-Carlo) of Barrett's esophagus and esophageal adenocarcinoma, including the evaluation of new endoscopic therapies to determine if they are cost-effective

- Quality of life and patient preferences in Barrett's esophagus

- Cost-Effectiveness of cancer chemoprevention (e.g. aspirin and/or selective COX-2 inhibitors)

- Technology assessment of "Virtual Colonoscopy" or computed tomographic colonography

 

Publications

Powered by Harvard Catalyst
  • Pandharipande PV, Heberle C, Dowling EC, Kong CY, Tramontano A, Perzan KE, Brugge W, Hur C. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology 2015; 275:177-87. PubMed
  • Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut 2015. PubMed
  • Swan JS, Kong CY, Hur C, Halpern EF, Itauma O, Williams O, Motazedi T, Lee JM. Comparing morbidities of testing with a new index: screening colonoscopy versus core-needle breast biopsy. J Am Coll Radiol 2015; 12:295-301. PubMed
  • Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle C, Miller M, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG. Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. Cancer Epidemiol Biomarkers Prev 2014. PubMed
  • Yachimski P, Wani S, Givens T, Howard E, Higginbotham T, Price A, Berman K, Hosford L, Katcher PM, Ozanne E, Perzan K, Hur C. Preference of Endoscopic Ablation Over Medical Prevention of Esophageal Adenocarcinoma by Patients With Barrett's Esophagus. Clin Gastroenterol Hepatol 2014. PubMed
  • Yasuda K, Choi SE, Nishioka NS, Rattner DW, Puricelli WP, Tramontano AC, Kitano S, Hur C. Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett's Esophagus. Dig Dis Sci 2014. PubMed
  • Choi SE, Perzan K, Tramontano AC, Kong CY, Hur C. Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. Cancer Prev Res (Phila Pa) 2014. PubMed
  • Shaheen NJ, Hur C. Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology 2013; 145:273-6. PubMed
  • Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013; 144:1024-30. PubMed
  • Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119:1149-58. PubMed
  • Yeh JM, Hur C, Schrag D, Kuntz KM, Ezzati M, Stout N, Ward Z, Goldie SJ. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med. 2013; 10:e1001451. PubMed
  • Ladabaum U, Brill JV, Sonnenberg A, Shaheen NJ, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha PJ. How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value. Gastroenterology 2012. PubMed
  • Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611-20. PubMed
  • Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ, . A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 2012; 143:917-26.e1. PubMed
  • Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012; 143:567-75. PubMed
  • Choi SE, Hur C. Screening and surveillance for Barrett's esophagus: current issues and future directions. Curr Opin Gastroenterol 2012; 28:377-81. PubMed
  • Omer ZB, Ananthakrishnan A, Nattinger KJ, Cole EB, Lin JJ, Kong CY, Hur C. Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. Clin Gastroenterol Hepatol 2012. PubMed
  • Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis 2012. PubMed
  • Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C. The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model. Cancer Epidemiol Biomarkers Prev 2011. PubMed
  • Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Dig Dis Sci 2011. PubMed
  • Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. Am J Gastroenterol 2011. PubMed
  • Ho W, Broughton DE, Donelan K, Gazelle GS, Hur C. Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population. AJR Am J Roentgenol 2010; 195:393-7. PubMed
  • Yeh JM, Ho W, Hur C. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc 2010; 72:33-43. PubMed
  • Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116:2941-53. PubMed
  • Yachimski P, Lee RA, Tramontano A, Nishioka NS, Hur C. Secular Trends in Patients Diagnosed with Barrett's Esophagus. Dig Dis Sci 2010; 55:960-6. PubMed
  • Huang ES, Gazelle GS, Hur C. Consensus Guidelines in the Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis. Dig Dis Sci 2010; 55:852-60. PubMed
  • Hur C, Hayeck TJ, Yeh JM, Richards EB, Spechler SJ, Gazelle GS, Kong CY. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS ONE 2010; 5:e9483. PubMed
  • Greenblatt WH, Hur C, Knudsen AB, Evans JA, Chung DC, Gazelle GS. Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2009; 18:2677-84. PubMed
  • Hur C,Broughton DE,Kong CY,Ozanne EM,Richards EB,Truong T,Gazelle GS. Patient Preferences for the Chemoprevention of Colorectal Cancer. Dig Dis Sci 2009; 54:2207-14. PubMed
  • Yachimski P,Nishioka NS,Richards E,Hur C. Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol 2008; 6:1206-11. PubMed
  • Pandharipande PV,Harisinghani MG,Ozanne EM,Specht MC,Hur C,Lee JM,Gazelle GS. Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol 2008; 191:1308-19. PubMed
  • Hur C,Broughton DE,Ozanne E,Yachimski P,Nishioka NS,Gazelle GS. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2008; 103:2432-42. PubMed
  • Pandharipande PV, Gervais DA, Mueller PR, Hur C, Gazelle GS. Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis. Radiology 2008; 248:169-78. PubMed
  • Yeh JM,Kuntz KM,Ezzati M,Hur C,Kong CY,Goldie SJ. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 2008; 17:1179-87. PubMed
  • Hur C, Yachimski P. How useful is histologic confirmation of intestinal metaplasia in patients with long-segment Barrett's esophagus? Nat Clin Pract Gastroenterol Hepatol 2008; 5:140-1. PubMed
  • Choi MY, Lauwers GY, Hur C, Willett CG, Chung DC. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys 2007; 68:1584. PubMed
  • Hur C. Esophageal capsule endoscopy for Barrett's esophagus screening: a hard pill to swallow? Clin Gastroenterol Hepatol 2007; 5:307-9. PubMed
  • Hur C, Chung DC, Schoen RE, Gazelle GS. The management of small polyps found by virtual colonoscopy: results of a decision analysis. Clin Gastroenterol Hepatol 2007; 5:237-44. PubMed
  • Schoen RE, Hur C. What is the clinical importance of small polyps with regard to colorectal cancer screening? Nat Clin Pract Gastroenterol Hepatol 2006; 3:488-9. PubMed
  • Hur C, Wittenberg E, Nishioka NS, Gazelle GS. Quality of life in patients with various Barretts esophagus associated health states. Health Qual Life Outcomes 2006; 4:45. PubMed
  • Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. Clin Gastroenterol Hepatol 2006; 4:1017-24; quiz 976. PubMed
  • Hur C, Chan AT, Tramontano AC, Gazelle GS. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother 2006; 40:1052-63. PubMed
  • Hur C, Gazelle GS, Hsu EH, Halpern EF, Podolsky DK. The effect of prior colonic imaging on endoscopic productivity: potential impact of computed tomographic colonography. Clin Gastroenterol Hepatol 2005; 3:1124-7. PubMed
  • Jo WS, Bandipalliam P, Shannon KM, Niendorf KB, Chan-Smutko G, Hur C, Syngal S, Chung DC. Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol 2005; 3:1022-8. PubMed
  • Hur C, Simon LS, Gazelle GS. Analysis of aspirin-associated risks in healthy individuals. Ann Pharmacother 2004; 39:51-7. PubMed
  • Hur C, Wittenberg E, Nishioka NS, Gazelle GS. Patient preferences for the management of high-grade dysplasia in Barrett's esophagus. Dig Dis Sci 2005; 50:116-25. PubMed
  • Hur C, Gazelle GS, Zalis ME, Podolsky DK. An analysis of the potential impact of computed tomographic colonography (virtual colonoscopy) on colonoscopy demand. Gastroenterology 2004; 127:1312-21. PubMed
  • Hur C, Simon LS, Gazelle GS. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer 2004; 101:189-97. PubMed
  • Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004; 96:316-25. PubMed
  • Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 2003; 48:1273-83. PubMed
  • Swan JS, Hur C, Lee P, Motazedi T, Donelan K. Responsiveness of the testing morbidities index in colonoscopy. Value Health 2013; 16:1046-53. PubMed
  • Brown NA, Kovacs A, Lui CR, Hur C, Zaia JA, Mosley JW. Prevalence of antibody to human herpesvirus 6 among blood donors infected with HIV. Lancet 1988; 2:1146. PubMed
Hide